Pfizer's last bid to reverse Lilly's CDK4/6 early-stage takeover fails, as a second Ibrance study falters
Eli Lilly staged a coup over the summer, showing their CDK4/6 drug Verzenio could help prevent recurrence in early-stage breast cancer patients just 3 weeks after Ibrance, the Pfizer CDK4/6 that had long been the market leader, failed on a similar study.
The study added $18 billion in market cap to the large pharma, but it came with a wrinkle. Pfizer had another early-stage study set to roll out later this year, one that, if successful, could tip the scales back towards a balance.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,100+ biopharma pros reading Endpoints daily — and it's free.